Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a collaboration with TARA Mind, in partnership with Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The initiative also aims to expand mental health awareness within the veteran community, a group disproportionately affected by mental health conditions.
The partnership leverages the networks of TARA Mind and VETS to enhance veteran engagement in clinical research. This aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, which underscores the urgency of developing effective therapies for conditions like major depressive disorder. Helus Pharma is advancing its FDA Breakthrough Therapy-designated HLP003 program, a proprietary novel serotonergic agonist (NSA) designed to activate serotonin pathways believed to promote neuroplasticity.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary NSAs to address unmet mental health needs. The company’s pipeline includes HLP003, currently in Phase 3 for adjunctive treatment of major depressive disorder, and HLP004, a Phase 2 candidate for generalized anxiety disorder. The collaboration with TARA Mind and VETS is expected to accelerate recruitment for the PARADIGM trial, which is critical for demonstrating the efficacy and safety of HLP003.
The partnership also aims to raise awareness about mental health treatment options among veterans, who often face barriers to accessing care. By working with organizations that have direct connections to the veteran community, Helus Pharma hopes to build trust and facilitate participation in clinical trials. The company believes that durable improvements in mental health can be achieved through its NSA platform, which targets serotonin pathways to enhance neuroplasticity.
For more information about Helus Pharma and its pipeline, visit Helus.com. The full press release is available at https://ibn.fm/o9dCH.
